CompanyDeals

Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio

CompanyDrug

EMA CHMP Recommends Revocation of TAVNEOS Marketing Authorization Following Data Integrity Concerns in ADVOCATE Trial

Policy / Regulatory

China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality

Drug Farm Closes First Tranche of $55 Million Series D Financing to Advance First-in-Class Pipeline Across Multiple Therapeutic Areas
CompanyDeals

Drug Farm Closes First Tranche of $55 Million Series D Financing to Advance First-in-Class Pipeline Across Multiple Therapeutic Areas

CompanyDeals

Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development

Triastek Secures Strategic Financing to Advance 3D-Printed Oral Peptide Pipeline and Build Shanghai International R&D Center
CompanyDeals

Triastek Secures Strategic Financing to Advance 3D-Printed Oral Peptide Pipeline and Build Shanghai International R&D Center

CompanyDrug

Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors

CompanyDrug

LongBio Pharma Secures FDA IND Approval for Novel Anti-IgE Antibody LP-003 in Peanut Allergy, Expanding Global Allergic Disease Pipeline

CompanyDrug

Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer

CompanyDeals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma
CompanyDrug

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma

CompanyDrug

Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan